Tiantian She
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tiantian She has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Chong Chen
Department of Clinical Laboratory, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Tianjin, China
3 shared publications Lin Liu
Department of Clinical Laboratory, Tianjin Union Medical Center, Nankai University
3 shared publicationsBaocheng Gong
Department of Pediatric Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer
2 shared publicationsChen Huang
Department of Clinical Laboratory, Tianjin Union Medical Center, Nankai University
2 shared publicationsXiaoyan Hu
Department of Clinical Laboratory, Tianjin Union Medical Center, Nankai University
2 shared publicationsYuge Ni
Department of Clinical Laboratory, Tianjin Union Medical Center, Nankai University
2 shared publications
Latest Publications
- Open Access
- 28 October 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1904750
Bone marrow CD14+CD206+ M2-like monocyte-macrophages as a potential complementary biomarker for bone marrow MRD in high-risk neuroblastoma
Neuroblastoma (NB) is a highly aggressive pediatric malignancy, frequently associated with a substantial risk of bone marrow metastasis and recurrence. The persistence of minimal residual disease (MRD) remains the primary obstacle to successful treatment outcomes. Bone marrow minimal residual disease (MRD) assessment in high-risk neuroblastoma primarily relies on the direct detection of residual tumor cells. However, the accompanying immune-microenvironmental changes remain incompletely characterized. In this study, GD2-directed immunocytochemistry, complemented by GD2-based flow cytometry, was used for the reference classification of bone marrow disease status in a cohort of 143 patients with high-risk neuroblastoma. We evaluated a panel of peripheral blood biomarkers, identifying NSE, CRP, FBG, and D-dimer as exhibiting significant differences between MRD-positive and MRD-negative groups; however, these biomarkers demonstrated limited diagnostic utility, with area under the curve (AUC) values below 0.7. Importantly, bone marrow CD14 + CD206 + M2-like monocyte-macrophages showed discriminatory ability for GD2-defined bone marrow MRD status (AUC = 0.794), with an optimal threshold of 1.71×10 4 /mL. Additionally, the proportion of CD14 + CD206 + macrophages showed a positive correlation with GD2 positivity in bone marrow samples. These findings suggest that bone marrow CD14 + CD206 + M2-like monocyte-macrophages showed potential as an auxiliary immune biomarker associated with bone marrow MRD status in high-risk NB. These findings require validation in larger, independent cohorts.
- 28 October 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1904750
Open AccessBone marrow CD14+CD206+ M2-like monocyte-macrophages as a potential complementary biomarker for bone marrow MRD in high-risk neuroblastoma
Neuroblastoma (NB) is a highly aggressive pediatric malignancy, frequently associated with a substantial risk of bone marrow metastasis and recurrence. The persistence of minimal residual disease (MRD) remains the primary obstacle to successful treatment outcomes. Bone marrow minimal residual disease (MRD) assessment in high-risk neuroblastoma primarily relies on the direct detection of residual tumor cells. However, the accompanying immune-microenvironmental changes remain incompletely characterized. In this study, GD2-directed immunocytochemistry, complemented by GD2-based flow cytometry, was used for the reference classification of bone marrow disease status in a cohort of 143 patients with high-risk neuroblastoma. We evaluated a panel of peripheral blood biomarkers, identifying NSE, CRP, FBG, and D-dimer as exhibiting significant differences between MRD-positive and MRD-negative groups; however, these biomarkers demonstrated limited diagnostic utility, with area under the curve (AUC) values below 0.7. Importantly, bone marrow CD14 + CD206 + M2-like monocyte-macrophages showed discriminatory ability for GD2-defined bone marrow MRD status (AUC = 0.794), with an optimal threshold of 1.71×10 4 /mL. Additionally, the proportion of CD14 + CD206 + macrophages showed a positive correlation with GD2 positivity in bone marrow samples. These findings suggest that bone marrow CD14 + CD206 + M2-like monocyte-macrophages showed potential as an auxiliary immune biomarker associated with bone marrow MRD status in high-risk NB. These findings require validation in larger, independent cohorts.
- Open Access
- 1 December 2025
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 14 (12) , 9002-9014
Targeting CLIC6 with theaflavin enhances radiotherapy sensitivity in ER+/HER2− breast cancer
Background: Radiotherapy is a cornerstone of breast cancer treatment; however, estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) tumors frequently exhibit intrinsic radioresistance. Understanding the molecular mechanisms underlying this resistance is crucial for improving therapeutic outcomes. This study aims to identify key molecular determinants of intrinsic radioresistance in ER+/HER2− breast cancer and to explore potential radiosensitization strategies targeting these determinants. Methods: We integrated single-cell RNA sequencing (scRNA-seq) data from ER+/HER2− breast tumors before and after radiotherapy with transcriptomic profiles from The Cancer Genome Atlas (TCGA). A high-dimensional weighted gene co-expression network analysis (hdWGCNA) was employed to identify gene modules associated with clinical traits. Functional assays were conducted in ER+ breast cancer cells with chloride intracellular channel 6 (CLIC6) overexpression or knockdown. A molecular docking analysis revealed that theaflavin specifically interacts with CLIC6. Further, clonogenic assays and Cell Counting Kit-8 (CCK-8) proliferation assays were performed to validate the biological effects of theaflavin and CLIC6 following radiotherapy. Results: The hdWGCNA identified a luminal A-like gene module correlated with progesterone receptor (PR) positivity and low Ki67 expression, within which CLIC6 emerged as a key hub gene. Elevated CLIC6 expression enhanced radioresistance, whereas CLIC6 knockdown increased radiosensitivity. Molecular docking confirmed that theaflavin binds to CLIC6 with high affinity (binding energy −8.8 kcal/mol). Theaflavin treatment significantly enhanced radiosensitivity in wild-type and CLIC6-overexpressing cells but had no effect in CLIC6-knockdown or ER-negative (ER−) cells. Conclusions: This study identified CLIC6 as a novel gene associated with radioresistance in ER+/HER2− breast cancer and showed that theaflavin functions as a natural radiosensitizer in a CLIC6-dependent manner, consistent with its high-affinity interaction with CLIC6. Targeting CLIC6 may provide a promising strategy to enhance radiotherapy efficacy in this common breast cancer subtype.
- 1 December 2025
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 14 (12) , 9002-9014
Open AccessTargeting CLIC6 with theaflavin enhances radiotherapy sensitivity in ER+/HER2− breast cancer
Background: Radiotherapy is a cornerstone of breast cancer treatment; however, estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) tumors frequently exhibit intrinsic radioresistance. Understanding the molecular mechanisms underlying this resistance is crucial for improving therapeutic outcomes. This study aims to identify key molecular determinants of intrinsic radioresistance in ER+/HER2− breast cancer and to explore potential radiosensitization strategies targeting these determinants. Methods: We integrated single-cell RNA sequencing (scRNA-seq) data from ER+/HER2− breast tumors before and after radiotherapy with transcriptomic profiles from The Cancer Genome Atlas (TCGA). A high-dimensional weighted gene co-expression network analysis (hdWGCNA) was employed to identify gene modules associated with clinical traits. Functional assays were conducted in ER+ breast cancer cells with chloride intracellular channel 6 (CLIC6) overexpression or knockdown. A molecular docking analysis revealed that theaflavin specifically interacts with CLIC6. Further, clonogenic assays and Cell Counting Kit-8 (CCK-8) proliferation assays were performed to validate the biological effects of theaflavin and CLIC6 following radiotherapy. Results: The hdWGCNA identified a luminal A-like gene module correlated with progesterone receptor (PR) positivity and low Ki67 expression, within which CLIC6 emerged as a key hub gene. Elevated CLIC6 expression enhanced radioresistance, whereas CLIC6 knockdown increased radiosensitivity. Molecular docking confirmed that theaflavin binds to CLIC6 with high affinity (binding energy −8.8 kcal/mol). Theaflavin treatment significantly enhanced radiosensitivity in wild-type and CLIC6-overexpressing cells but had no effect in CLIC6-knockdown or ER-negative (ER−) cells. Conclusions: This study identified CLIC6 as a novel gene associated with radioresistance in ER+/HER2− breast cancer and showed that theaflavin functions as a natural radiosensitizer in a CLIC6-dependent manner, consistent with its high-affinity interaction with CLIC6. Targeting CLIC6 may provide a promising strategy to enhance radiotherapy efficacy in this common breast cancer subtype.
- Open Access
- 26 November 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1)
Bone marrow aspirate Cit-H3 was identified as a novel biomarker of minimal residual disease in neuroblastoma
Background: Neuroblastoma (NB) is the most prevalent extracranial solid tumor in children. Neutrophils release neutrophil extracellular traps (NETs) following intense or prolonged activation. Neutrophil elastase (ELA2) and citrullinated histone H3 (Cit-H3) are specific markers of NETs. Additionally, neuron-specific enolase (NSE) serves as a biomarker and can be used to monitor the condition of NB progression, assess treatment response, and predict recurrence. Methods: This study employed a retrospective study design, and all samples were collected prior to bone marrow aspiration for diagnosis. A total of 39 serum samples from patients diagnosed with NB by postoperative pathological bone marrow aspiration were included as the study subjects, and neutrophils, ELA2, and Cit-H3 were detected in the study subjects using ELISA. The blood routine data of 99 patients diagnosed with NB were collected, and these data were from patients different from those of the aforementioned 39 serum samples. And patients were divided into two groups, namely NB patients with positive bone marrow metastasis and those without metastasis, based on the result of bone marrow GD2 immunohistochemical staining. All data were statistically analyzed using IBM SPSS Statistics 26.0 and GraphPad Prism 9.0 software. Results: A positive correlation was identified between NB bone marrow minimal residual disease (MRD) positivity and haematological indices, including interleukin-2 (IL-2) ( p = 0.021), IL-6 ( p = 0.030), NSE ( p < 0.001), and Cit-H3 ( p < 0.001). And MRD was positively associated with blood neutrophils in bone marrow ( p < 0.05). Conclusions: This study demonstrates a significant correlation between NETs and MRDs, and found a positive correlation between bone marrow MRD + and the indicators of IL-2, IL-6, and NSE, as well as a positive correlation with bone marrow neutrophils. And Cit-H3 was identified as a new biomarker and found a positive correlation between Cit-H3 and bone marrow MRD + .
- 26 November 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1)
Open AccessBone marrow aspirate Cit-H3 was identified as a novel biomarker of minimal residual disease in neuroblastoma
Background: Neuroblastoma (NB) is the most prevalent extracranial solid tumor in children. Neutrophils release neutrophil extracellular traps (NETs) following intense or prolonged activation. Neutrophil elastase (ELA2) and citrullinated histone H3 (Cit-H3) are specific markers of NETs. Additionally, neuron-specific enolase (NSE) serves as a biomarker and can be used to monitor the condition of NB progression, assess treatment response, and predict recurrence. Methods: This study employed a retrospective study design, and all samples were collected prior to bone marrow aspiration for diagnosis. A total of 39 serum samples from patients diagnosed with NB by postoperative pathological bone marrow aspiration were included as the study subjects, and neutrophils, ELA2, and Cit-H3 were detected in the study subjects using ELISA. The blood routine data of 99 patients diagnosed with NB were collected, and these data were from patients different from those of the aforementioned 39 serum samples. And patients were divided into two groups, namely NB patients with positive bone marrow metastasis and those without metastasis, based on the result of bone marrow GD2 immunohistochemical staining. All data were statistically analyzed using IBM SPSS Statistics 26.0 and GraphPad Prism 9.0 software. Results: A positive correlation was identified between NB bone marrow minimal residual disease (MRD) positivity and haematological indices, including interleukin-2 (IL-2) ( p = 0.021), IL-6 ( p = 0.030), NSE ( p < 0.001), and Cit-H3 ( p < 0.001). And MRD was positively associated with blood neutrophils in bone marrow ( p < 0.05). Conclusions: This study demonstrates a significant correlation between NETs and MRDs, and found a positive correlation between bone marrow MRD + and the indicators of IL-2, IL-6, and NSE, as well as a positive correlation with bone marrow neutrophils. And Cit-H3 was identified as a new biomarker and found a positive correlation between Cit-H3 and bone marrow MRD + .
- Open Access
- 1 August 2023
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 12 (8) , 2128-2137
Prognostic role of serum soluble ST2 of advanced breast cancer patients: a retrospective cohort study
Background: The soluble suppression of tumorigenicity 2 receptor (sST2) binds to interleukin-33 (IL-33) and blocks IL-33 and ST2 binding, suggesting that sST2 acts as a “decoy” receptor for IL-33 and is involved in the malignant progression of breast cancer. This paper aimed to investigate the differences in sST2 expression in patients with different molecular subtypes of breast cancer and assess its clinical value in the prognostic evaluation of advanced breast cancer. Methods: In this paper, we collected sera from 91 patients firstly diagnosed with advanced breast cancer at the Tianjin Medical University Cancer Institute and Hospital from 2008 to 2021 during their first hospitalization. We detected the expression level of sST2 in the serum of patients with different molecular fractions of breast cancer and analyzed the relationship between serum sST2 levels and breast cancer-related bone metastasis, cardiotoxicity, and overall survival. Bone metastases were detected using the Emission Computed Tomography technique, and chemotherapy drug-induced cardiotoxicity was detected by echocardiography. The Overall Survival was evaluated using the Kaplan–Meier estimator, and multivariate Cox regression analysis was performed to demonstrate the association between variables and sST2 levels. Results: Serum sST2 levels did not vary among the different pathological types, molecular types, and estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and tumor proliferation marker (Ki-67) subgroups, and only differed significantly in the cardiotoxicity group. There were no statistical differences in tissue polypeptide specific antigen (TPSA), carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA), carbohydrate antigen 153 (CA153), D-dimer, and inflammatory indexes neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) among different molecular subgroups. However, except for triple-negative breast cancer (TNBC), there was no difference in peripheral blood soluble ST2 concentrations among other molecular subtypes. Meanwhile, the survival of the high sST2 level group among advanced breast cancer patients was significantly lower than that of the normal group, and sST2 expression was closely related to cardiotoxicity and clinical stage. Conclusions: Serum sST2 is not only traditionally applied to the assessment of cardiac injury, but can also be utilized for assessing the prognosis of advanced breast cancer, excluding the influence of clinical stage and cardiotoxicity.
- 1 August 2023
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 12 (8) , 2128-2137
Open AccessPrognostic role of serum soluble ST2 of advanced breast cancer patients: a retrospective cohort study
Background: The soluble suppression of tumorigenicity 2 receptor (sST2) binds to interleukin-33 (IL-33) and blocks IL-33 and ST2 binding, suggesting that sST2 acts as a “decoy” receptor for IL-33 and is involved in the malignant progression of breast cancer. This paper aimed to investigate the differences in sST2 expression in patients with different molecular subtypes of breast cancer and assess its clinical value in the prognostic evaluation of advanced breast cancer. Methods: In this paper, we collected sera from 91 patients firstly diagnosed with advanced breast cancer at the Tianjin Medical University Cancer Institute and Hospital from 2008 to 2021 during their first hospitalization. We detected the expression level of sST2 in the serum of patients with different molecular fractions of breast cancer and analyzed the relationship between serum sST2 levels and breast cancer-related bone metastasis, cardiotoxicity, and overall survival. Bone metastases were detected using the Emission Computed Tomography technique, and chemotherapy drug-induced cardiotoxicity was detected by echocardiography. The Overall Survival was evaluated using the Kaplan–Meier estimator, and multivariate Cox regression analysis was performed to demonstrate the association between variables and sST2 levels. Results: Serum sST2 levels did not vary among the different pathological types, molecular types, and estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and tumor proliferation marker (Ki-67) subgroups, and only differed significantly in the cardiotoxicity group. There were no statistical differences in tissue polypeptide specific antigen (TPSA), carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA), carbohydrate antigen 153 (CA153), D-dimer, and inflammatory indexes neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) among different molecular subgroups. However, except for triple-negative breast cancer (TNBC), there was no difference in peripheral blood soluble ST2 concentrations among other molecular subtypes. Meanwhile, the survival of the high sST2 level group among advanced breast cancer patients was significantly lower than that of the normal group, and sST2 expression was closely related to cardiotoxicity and clinical stage. Conclusions: Serum sST2 is not only traditionally applied to the assessment of cardiac injury, but can also be utilized for assessing the prognosis of advanced breast cancer, excluding the influence of clinical stage and cardiotoxicity.